微RNA在心力衰竭病理生理进程中的研究进展  

Research Progress of MicroRNA in Pathophysiology Process of Heart Failure

作　　者：宿宁 田猛 罗玉梅[3] 万新红[4] 

机构地区：[1]广东医科大学研究生学院,广东湛江524023 [2]广东医科大学附属医院心血管内科,广东湛江524023 [3]深圳市龙岗区人民医院心血管内科,广东深圳518172 [4]深圳市龙岗区妇幼保健院心血管内科,广东深圳518172

出　　处：《医学综述》2018年第1期46-50,共5页Medical Recapitulate

摘　　要：微RNA(miRNA)是一种由21~25个核苷酸组成,非编码高度保守的内源性RNA分子。其与信使RNA上的3'非翻译区靶位点结合,促进信使RNA的降解或抑制信使RNA的翻译,负性调节蛋白质的表达。近年来,miRNA在心血管相关疾病方面的研究已成为热点,它主要通过影响心肌细胞的能量代谢、心肌纤维化、心室重构、心肌细胞的自律性来参与心力衰竭发生、发展的病理生理过程。因此,研究miRNA与这些病理生理过程的关系,寻找逆转这些过程的关键miRNA作用靶点,将为治疗心力衰竭提供理论支持。MicroRNA（miRNA） is a type of non-coding highly conserved endogenous RNA molecules consisting of 21- 25 nucleotides. It binds to the 3＇untranslated region target site on messenger RNA, promotes the degradation of messenger RNA or inhibits the translation of messenger RNA and negatively regulates protein expression. In recent years, the study of miRNA in cardiovascular related disease has become a hot topic. It mainly affects energy metabolism of cardiomyocytes, myocardial fibrosis, ventricular remodeling, myocardial fibrosis and automaticity of cardiomyocytes to participate in the pathophysiologic process of the occurrence and development of heart failure. Therefore, studying the relationship between miRNA and these pathophysiological processes and finding the key miRNA targets for reversing these processes will provide theoretical support for the treatment of heart failure.

关 键 词：心力衰竭 微RNA 心室重构 心肌纤维化 心律失常 

分 类 号：R541.6[医药卫生—心血管疾病]